Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zymeworks Inc ZYME

Healthcare Biotechnology
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based... see more

Recent & Breaking News (NDAQ:ZYME)

Zymeworks Added to Nasdaq Biotechnology Index

GlobeNewswire December 15, 2023

Zymeworks Announces Participation in Upcoming Investor Conference

GlobeNewswire November 30, 2023

Zymeworks Provides Corporate Update and Reports Third Quarter 2023 Financial Results

GlobeNewswire November 7, 2023

Zymeworks Announces Participation in Upcoming Investor Conferences

GlobeNewswire November 1, 2023

Zymeworks To Host Third Quarter 2023 Results Conference Call

GlobeNewswire October 17, 2023

Zymeworks Announces New Director Nominee

GlobeNewswire October 16, 2023

Zymeworks Provides Corporate Update and Reports Second Quarter 2023 Financial Results

GlobeNewswire August 10, 2023

Zymeworks Announces Participation in Upcoming Investor Conferences

GlobeNewswire August 1, 2023

Zymeworks To Host Second Quarter 2023 Results Conference Call

GlobeNewswire July 19, 2023

Zymeworks Announces Participation in Upcoming Investor Conference

GlobeNewswire July 3, 2023

Zymeworks Appoints New Director

GlobeNewswire June 29, 2023

Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes

GlobeNewswire June 26, 2023

Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

PR Newswire June 2, 2023

Zymeworks Announces Participation in Upcoming Investor Conferences

GlobeNewswire June 1, 2023

Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer

GlobeNewswire May 18, 2023

Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results

GlobeNewswire May 8, 2023

Zymeworks Announces Participation in Upcoming Investor Conferences

GlobeNewswire May 1, 2023

Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting

GlobeNewswire April 18, 2023

Zymeworks To Host First Quarter 2023 Results Conference Call

Business Wire April 17, 2023

Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors

Business Wire April 10, 2023